Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Povidone iodine extended release - IVIEW Therapeutics

Next Previous
Drug Profile

Povidone iodine extended release - IVIEW Therapeutics

Alternative Names: In-situ gel povidone iodine ophthalmic drop - IVIEW Therapeutics; IVIEW 1201; IVIEW-1503; Povidone iodine slow releasing eye drop - IVIEW Therapeutics; Sustained release povidone iodine nasal spray - IVIEW Therapeutic; Sustained release povidone iodine ophthalmic drop - IVIEW Therapeutics

Latest Information Update: 15 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator IVIEW Therapeutics
  • Class Antiseptics; Antivirals; Disinfectants; Eye disorder therapies; Oxidants; Pyrrolidinones; Skin disorder therapies
  • Mechanism of Action Bacterial protein inhibitors; Bacterial protein modulators; Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Bacterial conjunctivitis; Conjunctivitis
  • Preclinical COVID 2019 infections

Most Recent Events

  • 05 May 2025 IVIEW Therapeutics anticipates FDA’s agreement on phase III pivotal study plans in May 2025
  • 05 May 2025 IVIEW Therapeutics plans a phase III trial for Bacterial conjunctivitis
  • 18 Jun 2024 IVIEW Therapeutics plans a phase II trial for Keratitis in December 2024 (Ophthalmic, solution) (NCT06463678)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top